News

According to SurgiQuest, its technology offers superior access during minimally invasive surgical procedures because it allows the surgeon to operate with an unprecedented degree of freedom. The AirSeal

Abbott has opened a new pharmaceutical analytical research laboratory in Singapore’s Biopolis research park. This new facility is Abbott’s first pharmaceutical research and development site in Southeast Asia.

The study was designed to elicit potential adverse effects from a single, very large dose of hGH-CTP, also known as MOD-4023. No adverse effects were observed, and the

Oscient filed this lawsuit under the Hatch-Waxman Act in response to the Paragraph IV certification notice received by the company from Lupin advising the company of the filing

In May 2008, the FDA approved the first Prochymal expanded access program for the treatment of pediatric graft versus host disease (GVHD) patients. Congress and the FDA created

The trials are planned to begin in medical centers in Israel and in the US as soon as local regulatory approvals and agreements with the medical centers are

To date, the company has enrolled more than 70 subjects and participating clinical sites will be permitted to enroll additional subjects until February 10, 2009. This randomized trial

DexCom said that this revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the US.

This follow-on agreement, which involves technical support for the WebSDM software for use by the FDA Center for Drug Evaluation and Research review community, will help the FDA